Upload
shaiful-azmi-yahaya
View
113
Download
0
Embed Size (px)
Citation preview
Date JANUARY 2012
Renal denervation therapy: The 1st Malaysia experience
INSTITUT JANTUNG NEGARA DR. ROBAAYAH ZAMBAHARI DR. AZLAN HUSSEIN DR. SHAIFUL AZMI YAHAYA
Catheter-based treatment for renal symphatetic denervation
Treatment using the Symplicity Catheter
Transcatheter renal denervation trials: Chronology
The burden of hypertension in Malaysia
• The prevalence of hypertension in Malaysians aged 30 years and above was 42.6% in 2006
• 4.8 million individuals with hypertension in Malaysia• 3rd National health and morbidity survey in 2006
revealed 2/3 of individuals in Malaysia with hypertension were unaware that they have hypertension
• Only 26% of Malaysian patients achieved blood pressure control while on treatment
Source: MOH/P/PAK/158/Malaysia clinical practice guidelines for the management of hypertension 2008 (3rd edition)
Transcathether renal denervation for the treatment of resistant hypertension: The first
IJN experience
• Setting up resistant hypertension clinic• IJN (Malaysian National Heart Institute) is the first centre in
Asia to perform the renal denervation on the 11th September 2010.
• Performed using the Symplicity Cathether system (Ardian Medtronic)
• Presence of a proctor- Dr. Justin Davies (Interventional cardiologist and Walport clinical lecturer at Imperial College, London)
IJN resistant hypertension clinic website and facebook page
Methods• Patients referred to IJN resistant hypertension
clinic• Stratified based on inclusion and exclusion
criteria• Medication compliance assessment• Ambulatory blood pressure
monitoring/investigations• Screening for secondary hypertension• Consented for renal denervation therapy• Follow up
Inclusion criterias
• Based on the SYMPLICITY-HTN 2 trial• Systolic BP of more than 160 mmHg based on
average 3 office BP reading previously measured (more than 150 mmHg for type 2 DM)
• Patient is adhering to a stable 3 or more antihypertensive medications
• Patient is 18-85 years of age
Exclusion criterias• Renal artery abnormalities ( Renal artery stenosis,
diameter less than 4mm or 20mm in length)• EGFR of less than (45ml/min/1.73m2) based on MDRD
calculation criteria• Type 1 diabetes mellitus• Recent MI, Unstable angina and CVA within the last 6
months or scheduled or planned surgery in the next 6 months
• Haemodynamically significant valvular heart disease• Pregnant, nursing or planning to be pregnant
Patient group
Period between August 2010 – January 2012
Patient Age distribution
Ethnic group and sex
Cardiovascular risk factors
Antihypertensive medications
N= 39Resistant Hypertension=25White coat HTN=14
*4 patients excluded
Classes of anti hypertensive medications
Average baseline office BP based on 3 previous outpatient clinic visits
prior to referral
Ambulatory BP results pre procedurePatient is on 4
antihypertensive medications
Results
• Blood pressure changes from baseline and at follow up (2 weeks, 1 month, 3 month, 6 month and 12 month)
• Acute procedural safety and chronic procedural safety
• EGFR and renal profile at 2 weeks, 1 month and 3 month follow up
• Fasting sugar and HBAIC at 6 month follow up• Composite cardiovascular endpoints (MACE)
Procedural analysis
EGFR at follow up post procedure
EGFR is preserved of at least more than 45 mls/min/1.73m2 during follow up
Transient drop in one of the patient
On average, the EGFR did not show any significant change
Results of ABPM at follow up: Average 24 hour ABPM
Results: Systolic BP (max)
Result: Diastolic BP (max)
Result: Mean BP
Results: Average 24 hour Systolic difference at F/U
Result: Average 24 hour Diastolic difference at F/U
•Average office-based BP in the renal-denervation group was reduced 32/12 mm Hg (average baseline 178/96 mm Hg) six months after the ablation
•Between-group differences in BP at six months were 33/11 mm Hg (p<0.0001)
•Of the patients in the ablation arm, 84% had a 10-mm-Hg or greater drop in SBP vs 35% of controls (p<0.0001)
•There did not appear to be any adverse events:
Imaging of renal arteries for damage showed no evidence of renal artery stenosis or aneurysmal dilatation during the six-month follow-up . There were no changes in renal function, even in those with mild to moderate renal failure
SYMPLICITY HTN-2: Results
Conclusions
• Percutaneous catheter-based theraputic renal denervation is safe and simple
• Symplicity 2 study has shown that there is BP lowering benefit with no significant decline in renal function
• Longer follow up is necessary to observe further response to BP stabilization in our small cohort